Skip to content

Study · Animal study (in vivo) · mouse · 2011

9 results

Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice.

Oh YK, Bachar AR, Zacharias DG, Kim SG, Wan J, Cobb LJ, Lerman LO, Cohen P, Lerman A

Atherosclerosis25 Jun 2011Cited by 97 (Europe PMC)

PMID21763658 (opens in a new tab)PMCIDPMC3885346 (opens in a new tab)DOI10.1016/j.atherosclerosis.2011.06.038 (opens in a new tab)PepBankPUB-21763658
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-deficient mice fed a high cholesterol diet, daily intraperitoneal HNGF6A for 16 weeks prevented endothelial dysfunction.

    In plain wordsIn mice prone to artery disease, a humanin analogue given daily for 16 weeks prevented damage to the blood vessel lining.

    Peptide
    Humanin
    Outcome
    DecreaseEndothelial dysfunction
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Lung injury and fibrosis · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Daily intraperitonial injection of the HN analogue HNGF6A for 16 weeks prevented endothelial dysfunction
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-deficient mice fed a high cholesterol diet, HNGF6A for 16 weeks decreased atherosclerotic plaque size in the proximal aorta.

    In plain wordsIn mice prone to artery disease, a humanin analogue given for 16 weeks shrank fatty plaques in the main artery.

    Peptide
    Humanin
    Outcome
    DecreaseAtherosclerotic plaque size in proximal aorta
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Daily intraperitonial injection of the HN analogue HNGF6A for 16 weeks prevented endothelial dysfunction and decreased atherosclerotic plaque size in the proximal aorta of ApoE-deficient mice fed on a high cholesterol diet, without showing direct vasoactive effects or cholesterol-reducing effects.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    HNGF6A did not show direct vasoactive effects in ApoE-deficient mice.

    In plain wordsIn mice prone to artery disease, a humanin analogue did not directly widen or narrow blood vessels.

    Peptide
    Humanin
    Outcome
    No significant changeDirect vasoactive effects
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Lung injury and fibrosis · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Daily intraperitonial injection of the HN analogue HNGF6A for 16 weeks prevented endothelial dysfunction and decreased atherosclerotic plaque size in the proximal aorta of ApoE-deficient mice fed on a high cholesterol diet, without showing direct vasoactive effects or cholesterol-reducing effects.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    HNGF6A did not show cholesterol-reducing effects in ApoE-deficient mice fed a high cholesterol diet.

    In plain wordsIn mice prone to artery disease, a humanin analogue did not lower cholesterol.

    Peptide
    Humanin
    Outcome
    No significant changeCholesterol-reducing effect
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Daily intraperitonial injection of the HN analogue HNGF6A for 16 weeks prevented endothelial dysfunction and decreased atherosclerotic plaque size in the proximal aorta of ApoE-deficient mice fed on a high cholesterol diet, without showing direct vasoactive effects or cholesterol-reducing effects.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In ApoE-deficient mice, HNGF6A treatment reduced apoptosis in aortic plaques.

    In plain wordsIn mice prone to artery disease, a humanin analogue reduced cell death in artery plaques.

    Peptide
    Humanin
    Outcome
    DecreaseApoptosis in aortic plaques
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    HNGF6A treatment reduced apoptosis and nitrotyrosine immunoreactivity in the aortic plaques without affecting the systemic cytokine profile.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In ApoE-deficient mice, HNGF6A treatment reduced nitrotyrosine immunoreactivity in aortic plaques.

    In plain wordsIn mice prone to artery disease, a humanin analogue lowered a marker of oxidative damage in artery plaques.

    Peptide
    Humanin
    Outcome
    DecreaseNitrotyrosine immunoreactivity in aortic plaques
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    HNGF6A treatment reduced apoptosis and nitrotyrosine immunoreactivity in the aortic plaques without affecting the systemic cytokine profile.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    HNGF6A treatment did not affect the systemic cytokine profile in ApoE-deficient mice.

    In plain wordsIn mice prone to artery disease, a humanin analogue did not change blood levels of inflammation signals.

    Peptide
    Humanin
    Outcome
    No significant changeSystemic cytokine profile
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    HNGF6A treatment reduced apoptosis and nitrotyrosine immunoreactivity in the aortic plaques without affecting the systemic cytokine profile.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In ApoE-deficient mice, HNGF6A preserved the expression of endothelial nitric oxide synthase in the aorta.

    In plain wordsIn mice prone to artery disease, a humanin analogue kept up levels of an enzyme that helps blood vessels relax.

    Peptide
    Humanin
    Outcome
    IncreaseAortic endothelial nitric oxide synthase expression
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Lung injury and fibrosis · Cardiovascular
    Studied dose
    Dose not stated · intraperitoneal · 16 weeksAs given in this study (mouse).

    Source sentences

    Summary
    HNGF6A also preserved expression of endothelial nitric oxide synthase in aorta.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 09AnimalEndogenous levelAnimal study (in vivo)Other

    Humanin was expressed in the endothelial layer of the aortic plaques of ApoE-deficient mice.

    In plain wordsIn mice prone to artery disease, the body's own humanin was present in the blood vessel lining of artery plaques.

    Peptide
    Humanin
    Outcome
    Not applicableHumanin expression in aortic plaque endothelium
    Study

    mousen: not reported in source

    ApoE-deficient mice fed a high cholesterol diet
    Outcome group
    Lung injury and fibrosis · Cardiovascular

    Source sentences

    Summary
    HN was expressed in the endothelial layer on the aortic plaques.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.